https://crcwarriors.org/ 2026-05-27 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-05-27 daily 0.9 https://crcwarriors.org/medicamentos 2026-05-27 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-05-27 daily 0.8 https://crcwarriors.org/noticias 2026-05-27 daily 0.8 https://crcwarriors.org/combinaciones 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-05-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-05-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-05-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-05-01 monthly 0.7 https://crcwarriors.org/contacto 2026-05-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-05-01 monthly 0.6 https://crcwarriors.org/colabora 2026-05-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/biodiversidad-de-la-microbiota-intestinal-en-pacientes-con-tumores-solidos-tratados-con-inhibidores-de-puntos-de-control-inmunitario-icpi-un-estudio-prospectivo-monocentrico-para-identificar-las 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/gut-microbiota-gm-biodiversity-in-patients-with-solid-tumors-treated-with-immune-checkpoint-inhibitors-icis-a-monocenter-prospective-study-to-identify-the-interactions-between-gm-and-icis 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201259/analisis-de-las-diferencias-en-el-microbioma-intestinal-de-pacientes-con-cancer-y-diferentes-niveles-de-funcion-ovarica-y-resultados-de-fertilidad-tras-la-terapia-con-inhibidores-de-puntos-de-control 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-vacuna-genetica-para-el-tratamiento-de-tumores-solidos-con-inestabilidad-de-microsatelites 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04041310/nous-209-genetic-vaccine-for-the-treatment-of-microsatellite-unstable-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07604909/un-ensayo-aleatorizado-de-fase-ii-que-evalua-serplulimab-en-combinacion-con-quimioterapia-terapia-dirigida-de-segunda-linea-para-el-cancer-colorrectal-en-estadio-temprano-con-recurrencia-precoz-tras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07604909/a-phase-ii-randomized-trial-of-serplulimab-with-second-line-chemo-targeted-therapy-for-early-relapse-colorectal-cancer-after-adjuvant-chemotherapy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07605702/protocolo-del-registro-clinico-del-canopy-cancer-collective 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07605702/the-canopy-cancer-collective-clinical-registry-protocol 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07606963/sistema-robotico-triton-1-5-para-la-colonoscopia-diagnostica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07606963/triton-1-5-robotic-system-for-diagnostic-colonoscopy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/intervencion-con-alimentos-altamente-fermentados-en-pacientes-con-cancer-colorrectal-localmente-avanzado-el-estudio-feed 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/high-fermented-food-intervention-among-locally-advanced-rectal-cancer-patients-the-feed-trial 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07592793/estudio-comunitario-sobre-el-acceso-a-la-atencion-medica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07592793/community-gateway-to-health-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07220174/uso-del-software-gi-genius-tm-xr-en-un-visor-de-realidad-virtual-durante-una-colonoscopia-de-rutina 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220174/use-of-gi-genius-tm-xr-software-in-virtual-reality-headset-during-routine-colonoscopy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/estudio-que-evalua-la-neurotoxicidad-en-pacientes-con-cancer-gastrointestinal-metastasico-que-reciben-phycocare-r-o-placebo-durante-la-quimioterapia-basada-en-oxaliplatino 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/study-evaluating-neurotoxicity-in-patients-with-metastatic-gastro-intestinal-cancer-taking-phycocare-r-or-placebo-during-oxaliplatin-based-chemotherapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07487168/seguridad-y-eficacia-de-la-administracion-intraperitoneal-de-quimioterapia-pipac-con-mitomicina-como-agente-unico-en-tumores-solidos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07487168/safety-and-efficacy-of-pipac-using-single-agent-mitomycin-in-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07255664/un-ensayo-de-fase-i-iia-fih-que-evalua-la-viabilidad-de-la-administracion-de-inmunoterapia-basada-en-til-en-pacientes-con-crc-metastasico-y-cancer-de-pancreas 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07255664/a-fih-phase-i-iia-trial-assessing-feasibility-of-administrations-of-til-based-immunotherapy-in-patients-with-metastatic-crc-and-pc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/estudio-y-modulacion-de-las-respuestas-inmunitarias-en-los-canceres-colorrectales-primarios-y-metastasicos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435689/study-and-modulation-of-immune-responses-in-primary-and-metastatic-colon-cancers 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07492238/deteccion-multiomica-en-plasma-para-evaluar-la-eficacia-y-el-riesgo-de-recurrencia-en-la-terapia-de-conversion-en-el-cancer-colorrectal-oligo-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07492238/plasma-multi-omics-detection-for-evaluating-efficacy-and-recurrence-risk-in-oligometastatic-colorectal-cancer-conversion-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT00548236/el-ensayo-clinico-active-after-cancer-trial-aact 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT00548236/the-active-after-cancer-trial-aact 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04130971/prediccion-del-cancer-colorrectal-analisis-de-muestras-de-tejido-para-evaluar-las-caracteristicas-del-tumor-y-la-respuesta-al-tratamiento 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04130971/predicting-colorectal-cancer-tissue-samples-to-evaluate-tumour-characteristics-and-treatment-response 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06184594/evaluacion-de-la-eficacia-del-conjunto-de-herramientas-enav-para-mejorar-el-cribado-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06184594/evaluating-the-efficacy-of-the-enav-toolkit-to-improve-colorectal-cancer-screening 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04084249/vigilancia-guiada-por-ctdna-en-pacientes-con-cancer-colorrectal-en-estadio-iii-un-ensayo-clinico-aleatorizado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04084249/ctdna-guided-surveillance-for-stage-iii-crc-a-randomized-intervention-trial 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06167967/la-metilacion-del-adn-tumoral-circulante-como-guia-para-la-quimioterapia-adyuvante-postoperatoria-en-el-cancer-colorrectal-en-estadio-iii 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06167967/circulating-tumor-dna-methylation-guiding-postoperative-adjuvant-chemotherapy-in-stage-iii-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114627/impacto-del-genotipo-ces1-en-la-exposicion-a-capecitabina-en-pacientes-con-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114627/impact-of-ces1-genotype-on-capecitabine-exposure-in-cancer-patients 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337760/jovenes-adultos-con-canceres-gastrointestinales-y-neuroendocrinos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06759844/eficacia-de-un-programa-de-gestion-de-la-salud-a-traves-de-dispositivos-moviles-para-pacientes-supervivientes-de-cancer-colorrectal-con-enfermedades-cronicas 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06759844/effectiveness-of-a-mobile-health-management-program-for-colorectal-cancer-survivors-with-chronic-conditions 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06504901/evaluacion-de-la-eficacia-y-la-seguridad-de-un-anticuerpo-monoclonal-anti-pd-1-en-combinacion-con-rhg-csf-il-2-y-capeox-en-metastasis-hepaticas-sincronicas-de-cancer-colorrectal-inicialmente 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06504901/evaluation-of-efficacy-and-safety-of-pd-1-monoclonal-antibody-in-combination-with-rhg-csf-il-2-and-capeox-in-initially-resectable-synchronous-colorectal-liver-metastases 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07046585/evaluacion-de-la-prueba-de-deteccion-de-cancer-colorrectal-de-natera-en-una-poblacion-con-riesgo-promedio-find-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07046585/evaluation-of-the-natera-colorectal-cancer-screening-test-in-an-average-risk-population-find-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06477991/eficacia-de-la-estrategia-de-observacion-y-espera-o-de-la-cirugia-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-guiada-por-el-seguimiento-dinamico-de 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/the-efficacy-of-watch-and-wait-strategy-or-surgery-after-neoadjuvant-immunotherapy-for-locally-advanced-colorectal-cancer-with-dmmr-msi-h-guided-by-mrd-dynamic-monitoring-a-single-center-open-label 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-como-monoterapia-o-envafolimab-capeox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-monotherapy-or-envafolimab-capeox-as-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05507112/time-en-inmunoterapia-combinada-con-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05507112/time-in-immunotherapy-combined-with-ncrt-for-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345676/programa-de-divulgacion-para-la-deteccion-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345676/colorectal-cancer-screening-outreach 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/imagen-pet-de-dos-vartumabs-en-pacientes-con-tumores-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05428735/el-ensayo-dragon-2 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05428735/the-dragon-2-trial 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06136949/el-valor-terapeutico-diagnostico-de-stard3-en-el-cancer-colorrectal-el-estudio-star 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06136949/the-theranostic-value-of-stard3-in-colorectal-cancer-the-star-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/eficacia-de-sgm-101-para-la-delimitacion-del-tumor-primario-y-de-las-recurrencias-tumorales-y-metastasis-en-pacientes-sometidos-a-cirugia-por-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03659448/performance-of-sgm-101-for-the-delineation-of-primary-and-recurrent-tumor-and-metastases-in-patients-undergoing-surgery-for-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07564284/reseccion-hepatica-inicial-reseccion-intestinal-inicial-o-reseccion-simultanea-para-metastasis-hepaticas-sincronicas-de-cancer-colorrectal-resultados-calidad-de-vida-y-rentabilidad 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07564284/liver-first-bowel-first-or-simultaneous-resection-for-synchronous-colorectal-liver-metastases-outcomes-quality-of-life-and-cost-effectiveness 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06991452/diagnostico-precoz-y-seguimiento-de-la-recurrencia-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06991452/early-diagnosis-and-recurrence-monitoring-of-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07562711/estudio-aleatorizado-sobre-la-metilacion-del-ctdna-plasmatico-para-guiar-las-decisiones-sobre-la-quimioterapia-adyuvante-en-pacientes-con-cancer-colorrectal-t3n0-de-alto-riesgo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07562711/randomized-study-of-plasma-ctdna-methylation-to-guide-adjuvant-chemotherapy-decisions-in-high-risk-t3n0-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/estudio-sobre-la-seguridad-y-la-eficacia-de-la-tecnica-mr-linac-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/study-on-the-safety-and-efficacy-of-mr-linac-technique-in-patients-with-unresectable-locally-advanced-colon-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/ensayo-internacional-sobre-la-prevencion-de-metastasis-del-cancer-colorrectal-2 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/colorectal-metastasis-prevention-international-trial-2 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-mas-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-plus-celecoxib-for-dmmr-msi-h-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06884670/evaluacion-de-la-eficacia-y-la-seguridad-del-anticuerpo-monoclonal-anti-pd-1-en-combinacion-con-il-2-y-capeox-en-la-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-previo-a-la 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06884670/assessment-of-efficacy-and-safety-of-pd-1-monoclonal-antibody-combined-with-il-2-and-capeox-in-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-prior-to-surgery-a-prospective-multi-center 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07109440/el-papel-de-la-imagenologia-fapi-pet-ct-en-la-exploracion-del-microambiente-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07109440/the-role-of-the-imaging-fapi-pet-ct-in-exploring-the-microenvironment-of-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03708952/estilo-de-vida-y-habitos-alimenticios-en-relacion-con-las-lesiones-precursoras-del-cancer-colorrectal-y-las-enfermedades-cardiometabolicas 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03708952/lifestyle-and-dietary-pattern-in-relation-to-precursor-lesions-of-colorectal-cancer-and-cardiometabolic-diseases 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05220800/efectos-de-la-administracion-intravenosa-de-hierro-en-pacientes-con-deficiencia-de-hierro-y-cancer-colorrectal-que-no-presentan-anemia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05220800/effects-of-intravenous-administered-iron-in-non-anemic-iron-deficient-patients-with-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593678/tele-rehabilitacion-en-pacientes-con-cancer-optimizacion-de-la-prehabilitacion-y-la-rehabilitacion-tras-la-reseccion-de-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593678/telerehabilitation-in-cancer-patients-optimization-of-prehabilitation-and-rehabilitation-following-colorectal-resection 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204484/terapia-adyuvante-diferida-guiada-por-la-enfermedad-residual-minima-en-el-cancer-colorrectal-en-estadio-temprano-y-resecable 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204484/mrd-guided-deferred-adjuvant-therapy-in-resectable-early-stage-colon-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06557668/resultados-clinicos-del-tratamiento-con-inmunomoduladores-y-terapias-contra-el-cancer-en-pacientes-con-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06557668/clinical-outcomes-of-treatment-with-immunomodulator-plus-cancer-therapies-for-patients-with-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/toripalimab-como-tratamiento-neoadyuvante-con-o-sin-celecoxib-en-cancer-colorrectal-con-dmmr-msi-h 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/neoadjuvant-toripalimab-with-or-without-celecoxib-in-dmmr-msi-h-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07590856/resultados-preliminares-de-eficacia-de-sna028-en-pacientes-con-cancer-colorrectal-avanzado-con-expresion-positiva-de-gpa33 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07590856/a-preliminary-efficacy-of-sna028-in-patients-with-advanced-colorectal-cancer-positive-for-gpa33 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06615648/eficacia-de-una-intervencion-de-terapia-motivacional-para-reducir-el-consumo-de-alcohol-en-adultos-jovenes 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06615648/effectiveness-of-a-pmt-intervention-to-reduce-alcohol-in-young-adults 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-en-combinacion-con-regorafenib-como-tratamiento-de-tercera-linea-en-pacientes-con-crlm-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-combined-with-regorafenib-as-a-third-line-treatment-in-patients-with-mss-crlm 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06657222/primer-estudio-en-humanos-de-tub-030-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06657222/first-in-human-study-of-tub-030-in-patients-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985707/kn026-mas-quimioterapia-kn-046-en-cancer-colorrectal-y-carcinoma-biliar-her2-positivo 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985707/kn026-plus-chemotherapy-kn-046-in-her2-positive-colorectal-cancer-and-biliary-carcinoma 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06078670/inhibidor-de-parp-cvl218-en-terapia-combinada-para-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/parp-inhibitor-cvl218-in-combination-therapy-for-patients-with-advanced-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/hpv-ctdna-response-adapted-chemoradiation-retifanlimab-treatment-in-advanced-stage-anal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05038358/participacion-del-microambiente-tumoral-inmunitario-en-los-mecanismos-de-resistencia-a-la-quimioterapia-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05038358/tumor-immune-microenvironment-involvement-in-colorectal-cancer-chemoresistance-mechanisms 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06690593/caracteristicas-y-relevancia-clinica-de-la-microbiota-intestinal-en-pacientes-con-gammapatia-monoclonal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/quimiorradioterapia-neoadyuvante-mas-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-de-riesgo-intermedio-alto-segun-el-indice-de-inmunidad 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/neoadjuvant-chemoradiotherapy-plus-sintilimab-for-intermediate-high-immunoscore-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparacion-de-chidamide-sintilimab-bevacizumab-con-el-regimen-estandar-de-segunda-linea-folfiri-bevacizumab-en-pacientes-con-mcrc-avanzado-mss-pmmr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparing-chidamide-sintilimab-bev-with-standard-second-line-folfiri-bev-in-advanced-mss-pmmr-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-trastuzumab-quimioterapia-en-tumores-solidos-her2-cancer-colorrectal-y-cancer-de-mama 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-with-trastuzumab-chemotherapy-in-her2-solid-tumors-colorectal-and-breast-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885385/un-estudio-de-fase-ii-que-evalua-la-seguridad-y-la-eficacia-de-js207-con-o-sin-js015-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885385/a-phase-2-study-evaluating-the-safety-and-efficacy-of-js207-with-or-without-js015-in-combination-with-chemotherapy-in-patients-with-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07068529/desarrollo-y-validacion-de-biomarcadores-metabolicos-para-el-diagnostico-precoz-el-pronostico-y-la-deteccion-de-la-recurrencia-del-cancer-colorrectal-metbio-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07068529/development-and-validation-of-metabolic-biomarkers-for-early-diagnosis-prognosis-and-recurrence-of-colorectal-cancer-metbio-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/explorando-la-duracion-del-tratamiento-con-terapia-neoadyuvante-anti-pd-1-en-el-cancer-colorrectal-en-estadio-ii-iii-con-dmmr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/exploring-the-treatment-duration-of-pd-1-neoadjuvant-therapy-in-stage-ii-iii-dmmr-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/el-riesgo-a-largo-plazo-de-neoplasia-colorrectal-avanzada-despues-de-la-colonoscopia-un-estudio-de-cohorte-basado-en-la-poblacion-en-hong-kong 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/the-longterm-risk-of-advanced-colorectal-neoplasia-after-colonoscopy-a-population-based-cohort-study-in-hong-kong 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04074538/el-estudio-del-consorcio-nacional-de-investigacion-sobre-el-cancer-colorrectal-ncrcc-consorcio-nacional-de-investigacion-sobre-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04074538/the-national-colorectal-cancer-cohort-ncrcc-study-national-colorectal-cancer-research-consortium 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05794750/evaluar-la-eficacia-de-la-radioterapia-y-la-quimioterapia-secuencial-asi-como-de-ak104-antes-de-la-cirugia-de-reseccion-mesenterica-total-tme-en-el-cancer-colorrectal-local-ak104-iit-13 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05794750/assess-the-efficacy-of-radiotherapy-and-sequential-chemotherapy-and-ak104-before-tme-surgery-for-local-crc-ak104-iit-13 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07447050/riluzol-para-prevenir-la-disfuncion-cognitiva-en-pacientes-con-cancer-que-reciben-quimioterapia-refocus-ensayo-piloto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07447050/riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06099951/tratamiento-neoadyuvante-total-para-cancer-colorrectal-localmente-avanzado-con-pmmr-anticuerpo-anti-pd-1-con-folfoxiri-y-radioterapia-preoperatoria 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/total-neoadjuvant-treatment-for-pmmr-locally-advanced-low-rectal-cancer-anti-pd-1-antibody-with-folfoxiri-and-preoperative-radiation-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06079242/estudio-observacional-sobre-la-terapia-con-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-metastasicos-irresecables-procedentes-de-cancer-colorrectal-primario 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/observational-study-for-sir-spheres-therapy-for-the-treatment-of-unresectable-metastatic-liver-tumors-from-primary-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05321134/evaluacion-de-la-tecnologia-robotica-de-un-solo-puerto-single-port-sp-en-la-cirugia-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05321134/evaluation-of-single-port-sp-robotic-technology-in-colorectal-surgery 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06855849/un-estudio-de-fase-ii-abierto-de-un-solo-brazo-y-multicentrico-para-evaluar-la-eficacia-de-amivantamab-en-combinacion-con-folfiri-como-tratamiento-de-segunda-linea-en-pacientes-con-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06855849/an-open-label-single-arm-multicenter-phase-ii-study-to-evaluate-the-efficacy-of-amivantamab-in-combination-with-folfiri-as-a-second-line-treatment-in-patients-with-ras-braf-wild-type-advanced 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06577194/un-estudio-de-un-solo-centro-de-un-solo-brazo-sobre-radioterapia-neoadyuvante-de-curso-corto-con-il-2-seguida-de-inmunoterapia-secuencial-con-capox-combinada-con-un-anticuerpo-anti-pd-1-e-il-2-para 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06577194/a-single-center-single-arm-study-of-neoadjuvant-short-course-radiotherapy-with-il-2-followed-by-sequential-immunotherapy-with-capox-combined-with-pd-1-antibody-and-il-2-for-locally-advanced-rectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07144683/fistula-anastomotica-tras-la-cirugia-de-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07144683/anastomotic-leakage-after-colorectal-surgery 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07106463/microbiota-su-papel-en-la-inflamacion-cronica-la-enfermedad-inflamatoria-intestinal-y-el-riesgo-de-cancer-colorrectal-evaluacion-de-un-modelo-predictivo-pronostico-con-implicaciones-terapeuticas 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07106463/microbiota-its-role-in-chronic-inflammation-idb-and-risk-of-colorectal-cancer-evaluation-of-a-predictive-prognostic-model-with-therapeutic-implications 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05551052/deteccion-del-cancer-colorrectal-evaluacion-fiable-mediante-analisis-sanguineo 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05551052/crc-detection-reliable-assessment-with-blood 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06106165/mejorando-la-participacion-de-las-mujeres-musulmanas-en-los-programas-de-deteccion-del-cancer-imcan 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06106165/improving-muslim-women-s-uptake-of-cancer-screening-imcan 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/trasplante-de-la-microbiota-intestinal-para-el-tratamiento-de-la-caquexia-tumoral-avanzada 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07533227/intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03985891/la-eficacia-de-js001-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03985891/the-efficacy-of-js001-combined-with-chemotherapy-in-patients-with-locally-advanced-colon-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06696534/analisis-de-las-preferencias-de-los-participantes-en-relacion-con-los-metodos-de-deteccion-y-su-experiencia-en-un-programa-de-deteccion-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06696534/exploring-participant-preference-for-screening-methods-and-experience-into-colorectal-cancer-screening-programme 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/estudio-observacional-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-irresecables-registro-sirtain 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/observational-sir-spheres-study-for-the-treatment-of-unresectable-liver-tumors-sirtain-registry 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287671/omica-del-cancer-colorrectal-y-proteoglicanos-de-la-matriz-extracelular-ofcs 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287671/colorectal-omics-and-ofcs-proteoglycans 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07005453/precision-y-sostenibilidad-de-la-evaluacion-scale-eye-para-medir-el-tamano-de-los-polipos-de-forma-fiable 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07005453/accuracy-and-sustainability-of-scale-eye-evaluation-for-measuring-reliable-polyp-size 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05576896/hidroxicloroquina-en-combinacion-con-encorafenib-y-cetuximab-o-panitumumab-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mutacion-braf-refractario 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576896/hydroxychloroquine-in-combination-with-encorafenib-and-cetuximab-or-panitumumab-in-the-treatment-of-metastatic-braf-mutated-colorectal-cancer-refractory 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06972498/estudio-multicentrico-prospectivo-ivosimab-quimioterapia-como-tratamiento-neoadyuvante-para-metastasis-hepaticas-de-crc-pmmr-mss-resecable 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06972498/a-prospective-multicenter-study-ivosimab-chemotherapy-as-neoadjuvant-for-resectable-pmmr-mss-crc-liver-mets 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/tratamiento-antitumoral-sistemico-con-o-sin-quimioterapia-en-aerosol-intraabdominal-a-presion-para-metastasis-peritoneales-de-cancer-de-colon-pipox02 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555003/quimioterapia-con-debiri-mas-otros-farmacos-frente-a-quimioterapia-sola-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555003/debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06491355/tratamiento-de-primera-linea-con-el-regimen-mfolfox6-y-hlx04-seguido-de-la-combinacion-con-serplulimab-en-cancer-colorrectal-metastasico-inicialmente-irresecable-y-con-estado-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06491355/first-line-treatment-induced-with-mfolfox6-and-hlx04-regimen-following-combined-with-serplulimab-in-mss-initially-unresectable-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/un-estudio-para-caracterizar-el-uso-de-encorafenib-mas-cetuximab-como-tratamiento-de-reintroduccion-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-tras-una-terapia-previa-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/a-study-to-characterize-encorafenib-plus-cetuximab-as-rechallenge-treatment-for-braf-v600e-mutant-metastatic-colorectal-cancer-patients-after-previous-therapy-with-braf-inhibitors-based-combinations 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-un-estudio-para-obtener-mas-informacion-sobre-el-farmaco-de-estudio-denominado-pf-08634404-en-combinacion-con-quimioterapia-en-participantes-adultos-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07222800/symbiotic-gi-03-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03983993/niraparib-y-panitumumab-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03983993/niraparib-and-panitumumab-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/reseccion-anatomica-de-metastasis-hepaticas-en-pacientes-con-cancer-colorrectal-con-mutaciones-en-los-genes-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05970705/regorafenib-en-combinacion-con-tas-102-frente-a-regorafenib-en-monoterapia-en-la-terapia-de-tercera-linea-o-posterior-del-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970705/regorafenib-combined-with-tas-102-versus-regorafenib-monotherapy-in-third-or-later-line-therapy-of-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/evaluacion-del-farmaco-antitumoral-rogaratinib-bay-1163877-para-el-tratamiento-del-sarcoma-avanzado-con-alteracion-en-el-receptor-del-factor-de-crecimiento-de-fibroblastos-fgfr-1-4-y-en-pacientes-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/testing-the-anti-cancer-drug-rogaratinib-bay-1163877-for-treatment-of-advanced-sarcoma-with-alteration-in-fibroblast-growth-factor-receptor-fgfr-1-4-and-in-patients-with-sdh-deficient 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06287723/estudio-frances-sobre-la-evaluacion-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-french-mrd-crlm 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06287723/french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-french-mrd-crlm 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-en-combinacion-con-trifluridina-tipiracil-en-el-tratamiento-del-cancer-colorrectal-metastasico-refractario 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06343116/nimotuzumab-combined-with-trifluridine-tipiracil-in-the-treatment-of-refractory-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05746897/un-estudio-de-fase-i-abierto-multicentrico-y-de-primera-administracion-en-humanos-de-nm1f-anti-pvrig-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/a-first-in-human-phase-i-open-label-multicenter-study-of-nm1f-anti-pvrig-in-patients-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-zen003694-al-tratamiento-de-quimioterapia-habitual-capecitabina-para-canceres-metastasicos-o-irresecables 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05803382/testing-the-addition-of-an-anti-cancer-drug-zen003694-to-the-usual-chemotherapy-treatment-capecitabine-for-metastatic-or-unresectable-cancers 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/estudio-sobre-el-impacto-de-una-dieta-mediterranea-modificada-en-pacientes-con-cancer-colorrectal-que-reciben-tratamiento-oncologico-activo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07535632/radioterapia-estereotactica-ablativa-sbrt-seguida-de-un-inhibidor-de-pd-1-bevacizumab-y-tas-102-como-terapia-de-tercera-linea-para-el-cancer-colorrectal-recurrente-o-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07535632/sbrt-followed-by-pd-1-inhibitor-bevacizumab-and-tas-102-as-third-line-therapy-for-recurrent-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/un-estudio-exploratorio-de-la-sensibilidad-al-tratamiento-y-los-factores-pronosticos-en-un-estudio-de-eficacia-y-seguridad-de-mfolfox6-bevacizumab-frente-a-mfolfox6-panitumumab-en-pacientes-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394834/an-exploratory-study-of-treatment-sensitivity-and-prognostic-factors-in-a-efficacy-and-safety-study-of-mfolfox6-bevacizumab-versus-mfolfox6-panitumumab-therapy-in-patients-with-chemotherapy-naive 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/ensayo-clinico-prospectivo-de-seguridad-y-eficacia-sobre-la-terapia-con-aerosol-intraperitoneal-presurizado-para-la-metastasis-peritoneal-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/investigacion-en-la-practica-clinica-del-inhibidor-de-braf-encorafenib-y-el-cetuximab-como-tratamiento-de-nueva-generacion-para-el-ccrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/braf-inhibitor-encorafenib-and-cetuximab-real-life-investigation-of-next-generation-crc-treatment 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021950/ak112-mas-folfiri-frente-a-bevacizumab-mas-folfiri-como-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-mss-pmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07021950/ak112-plus-folfiri-versus-bevacizumab-plus-folfiri-as-second-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/ablacion-por-microondas-combinada-con-quimioterapia-para-metastasis-hepaticas-de-cancer-colorrectal-un-estudio-de-cohortes-multicentrico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04562727/microwave-ablation-combined-with-chemotherapy-for-colorectal-liver-metastases-a-multicenter-cohort-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06353854/cohorte-nacional-prospectiva-para-evaluar-biomarcadores-predictivos-de-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-dmmr-coresim 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/prospective-national-cohort-evaluating-predictive-biomarkers-of-resistance-to-immunotherapy-in-patients-with-msi-dmmr-metastatic-colorectal-cancer-coresim 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/tratamiento-estandar-de-segunda-linea-tratamiento-secuencial-con-tas-102-y-bevacizumab-combinado-con-tratamiento-local-en-cancer-colorrectal-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/second-line-standard-treatment-sequential-tas-102-and-bevacizumab-combined-with-local-treatment-in-advanced-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnostico-de-multiples-tipos-de-cancer-y-seguimiento-de-tumores-residuales-minimos-tras-el-tratamiento-mediante-el-analisis-de-sangre-y-tecnicas-geneticas-de-alta-sensibilidad 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02838836/deteccion-de-celulas-tumorales-y-adn-en-la-sangre-la-orina-y-la-medula-osea-de-pacientes-con-canceres-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02838836/tumor-cell-and-dna-detection-in-the-blood-urine-and-bone-marrow-of-patients-with-solid-cancers 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-msi-refractarios-a-anti-pd1 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05310643/nivolumab-and-ipilimumab-in-anti-pd1-resistant-dmmr-msi-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07025239/ql1706-en-inyeccion-combinado-con-bevacizumab-y-xelox-frente-a-placebo-combinado-con-bevacizumab-y-xelox-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07025239/ql1706-injection-plus-bevacizumab-and-xelox-vs-placebo-plus-bevacizumab-and-xelox-as-first-line-treatment-of-unresectable-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06643793/evaluacion-del-liposoma-de-irinotecan-ii-en-combinacion-con-5-fu-lv-y-bevacizumab-para-el-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/el-papel-de-un-ciclo-corto-de-radioterapia-paliativa-en-el-cancer-de-recto-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/the-role-of-short-course-of-palliative-radiation-in-metastatic-cancer-rectum 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-un-estudio-de-investigacion-clinica-que-evalua-eik1005-un-inhibidor-de-la-helicasa-de-werner-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/caracterizacion-molecular-de-las-metastasis-peritoneales-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/molecular-characterisation-of-colorectal-cancer-peritoneal-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-y-sintilimab-en-combinacion-con-electroacupuntura-en-crc-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bevacizumab-tislelizumab-para-el-tratamiento-de-primera-linea-del-mcrc-con-mss-pmmr-y-mutacion-en-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bev-tislelizumab-for-first-line-treatment-of-mss-pmmr-ras-mutated-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04831528/toma-de-decisiones-basada-en-el-ctdna-en-pacientes-con-mcrc-despues-del-fracaso-del-tratamiento-de-primera-linea-que-incluye-cetuximab-un-estudio-clinico-de-fase-ii-monocentrico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04831528/decision-making-of-ctdna-in-patients-with-mcrc-after-failure-of-first-line-treatment-containing-cetuximab-a-single-center-phase-ii-clinical-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/analisis-genomico-exhaustivo-de-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-aisladas-para-comprender-la-respuesta-y-la-resistencia-a-la-terapia-contra-el-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/comprehensive-genomic-profiling-of-colorectal-cancer-patients-with-isolated-liver-metastases-to-understand-response-resistance-to-cancer-therapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-68ga-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07587827/estudio-que-evalua-la-seguridad-la-viabilidad-y-la-eficacia-de-la-vacuna-odi-2001-una-inmunoterapia-personalizada-en-pacientes-con-cancer-colorrectal-metastasico-o-localmente-avanzado-o-cancer-de 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587827/study-evaluating-the-safety-feasibility-and-efficacy-of-odi-2001-vaccine-a-personnalized-immunotherapy-in-patients-with-metastatic-or-locally-advanced-colon-cancer-or-pancreatic-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03587480/reseccion-mesorrectal-total-rmt-con-diseccion-de-los-ganglios-linfaticos-laterales-frente-a-rmt-tras-quimiorradioterapia-neoadyuvante 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03587480/total-mesorectal-excision-tme-with-lateral-lymph-node-dissection-versus-tme-after-neoadjuvant-chemo-radiotherapy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparacion-de-la-hepatectomia-y-la-ablacion-local-para-el-tratamiento-de-metastasis-hepaticas-sincronicas-y-metacronicas-resecables-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparison-of-hepatectomy-and-local-ablation-for-resectable-synchronous-and-metachronous-colorectal-liver-metastasis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04743102/biopsia-multipunto-y-de-espesor-total-en-el-diagnostico-de-respuesta-clinica-completa-ccr-tras-la-terapia-neoadyuvante-para-el-cancer-de-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/multi-points-and-full-thickness-biopsy-in-the-diagnosis-of-ccr-after-neoadjuvant-therapy-for-rectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/imagenes-moleculares-con-fapi-para-el-diagnostico-del-subtipo-desfavorable-cms4-de-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/fapi-molecular-imaging-for-diagnosis-of-the-cms4-unfavorable-colorectal-cancer-subtype 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/un-estudio-para-investigar-cea-prit-2-0-en-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-colorectal-cancer-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/biopsia-liquida-cancer-de-pulmon-y-cancer-de-colon-en-andalucia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/liquid-biopsy-lung-and-colon-cancer-in-andalucia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-en-combinacion-con-bevacizumab-y-el-regimen-folfox-para-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-avanzado-irresecable-y-de-tipo-mss-con-mutacion-en-los-genes-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-in-combination-with-bevacizumab-and-folfox-regimen-for-the-first-line-treatment-of-advanced-unresectable-mss-type-ras-mutated-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04714957/pitcher-heterogeneidad-de-la-carcinomatosis-peritoneal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04714957/pitcher-peritoneal-carcinomatosis-heterogeneity 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulacion-de-la-microbiota-intestinal-mediante-una-dieta-preoperatoria-estandarizada-para-prevenir-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-tras-la-cirugia 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06349590/manipulation-of-the-gut-microbiome-by-a-standardized-preoperative-diet-to-prevent-colorectal-cancer-recurrence-and-metastasis-following-surgery 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05319314/gcc19cart-for-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03635021/estudio-para-evaluar-la-eficacia-de-folfox-panitumumab-seguido-de-folfiri-bevacizumab-secuencia-1-frente-a-folfox-bevacizumab-seguido-de-folfiri-panitumumab-secuencia-2-en-pacientes-no-tratados-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03635021/study-to-evaluate-the-efficacy-of-folfox-panitumumab-followed-by-folfiri-bevacizumab-sequence-1-versus-folfox-bevacizumab-followed-by-folfiri-panitumumab-sequence-2-in-untreated-patients-with-wild 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07079631/un-estudio-clinico-para-evaluar-si-un-tratamiento-experimental-denominado-bnt314-utilizado-en-combinacion-con-otro-tratamiento-experimental-bnt327-y-quimioterapia-es-beneficioso-y-seguro-para 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079631/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt314-when-used-in-combination-with-another-investigational-treatment-bnt327-and-chemotherapy-is-beneficial-and-safe-for-patients-with 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150403/quimioterapia-combinada-de-segunda-linea-folfox-o-folfiri-mas-fruquintinib-frente-a-quimioterapia-combinada-folfox-o-folfiri-mas-bevacizumab-en-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/second-line-doublet-chemotherapy-folfox-or-folfiri-plus-fruquintinib-versus-doublet-chemotherapy-folfox-or-folfiri-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-en-combinacion-con-pemetrexed-para-el-tratamiento-de-tumores-solidos-metastasicos-con-delecion-de-mtap 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594626/bms-986504-in-combination-with-pemetrexed-for-the-treatment-of-metastatic-solid-tumors-with-mtap-deletion 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/estudio-de-sotorasib-panitumumab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-con-mutacion-kras-p-g12c-que-no-han-recibido-tratamiento-previo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-awwb-in-treatment-naive-participants-with-metastatic-colorectal-cancer-with-kras-p-g12c-mutation 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/estudio-de-hidroxicloroquina-con-folfiri-y-bevacizumab-en-cancer-colorrectal-metastasico-con-alto-nivel-de-dtp 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/study-of-hydroxychloroquine-with-folfiri-and-bevacizumab-in-dtp-high-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03326791/aspirina-en-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03326791/aspirin-in-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05832138/ensayo-onloop-evaluacion-de-un-nuevo-sistema-de-seguimiento-y-apoyo-para-los-supervivientes-de-cancer-infantil-en-ontario 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05832138/onloop-trial-evaluating-a-new-surveillance-and-support-system-for-survivors-of-childhood-cancer-in-ontario 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06053996/radioesterilizacion-hepatopulmonar-combinada-con-inmunoterapia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06053996/hepatopulmonary-radio-sterilization-with-immunotherapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04701476/tate-y-pembrolizumab-mk3475-en-el-tratamiento-del-mcrc-y-el-nsclc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotina-en-combinacion-con-cetuximab-en-el-tratamiento-en-lineas-posteriores-del-cancer-colorrectal-metastasico-con-ras-tipo-salvaje 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07490119/becotatug-vedotin-combined-with-cetuximab-in-the-later-line-treatment-of-metastatic-ras-wild-type-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07310537/viabilidad-del-analisis-del-adn-tumoral-circulante-ctdna-mediante-la-extraccion-automatizada-de-muestras-de-sangre-capilar 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310537/feasibility-of-circulating-tumour-dna-ctdna-analysis-using-automated-capillary-blood-sampling 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04046445/estudio-de-fase-1b-para-evaluar-atp128-vsv-gp128-y-bi-754091-en-pacientes-con-cancer-colorrectal-en-estadio-iv 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/phase-1b-study-to-evaluate-atp128-vsv-gp128-and-bi-754091-in-patients-with-stage-iv-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-mas-s-1-y-raltitrexed-rsf-para-el-cmmr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06427005/fruquintinib-plus-s-1-and-raltitrexed-rsf-for-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/ensayo-de-fase-i-ii-de-s241656-en-malignidades-seleccionadas-con-mutaciones-ras-mapk 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/phase-1-2-trial-of-s241656-in-selected-ras-mapk-mutation-positive-malignancies 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06665087/radioterapia-ultrafraccionada-guiada-por-cga-y-tratamiento-sistemico-de-primera-linea-en-pacientes-ancianos-o-fragiles-con-cmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/cga-guided-ultrafractionated-rt-and-first-line-systemic-treatment-in-elderly-or-frail-patients-with-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03803553/identificacion-y-tratamiento-de-la-enfermedad-micrometastasica-en-el-cancer-de-colon-en-estadio-iii 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03803553/identification-and-treatment-of-micrometastatic-disease-in-stage-iii-colon-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants-with 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03451370/tratamiento-de-primera-linea-con-la-combinacion-de-capecitabina-y-oxaliplatino-mas-bevacizumab-en-pacientes-ancianos-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03451370/first-line-combination-of-capecitabine-and-oxaliplatin-plus-bevacizumab-in-elderly-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/eficacia-del-fruquintinib-modificado-en-metastasis-hepaticas-del-cancer-colorrectal-un-estudio-de-fase-ii 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06018714/efficacy-of-modified-fruquintinib-in-colorectal-cancer-liver-metastases-a-phase-ii-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04874259/terapia-local-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04874259/lt-for-unresectable-colorectal-liver-metastasis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05725200/estudio-para-investigar-los-resultados-de-un-tratamiento-individualizado-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05725200/study-to-investigate-outcome-of-individualized-treatment-in-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06505551/estudio-de-fase-i-ii-de-celulas-t-con-receptores-de-celulas-t-autologas-scg142-en-pacientes-con-carcinoma-positivo-para-hpv16-52 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/phase-1-2-study-of-autologous-scg142-tcr-t-cells-in-patients-with-hpv16-52-positive-carcinoma 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04963283/estudio-de-cabozantinib-y-nivolumab-en-cancer-colorrectal-metastasico-refractario-y-con-estabilidad-de-microsatelites-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04963283/study-of-cabozantinib-and-nivolumab-in-refractory-metastatic-microsatellite-stable-mss-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434090/irinotecan-liposomal-mas-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario-a-irinotecan 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06434090/liposomal-irinotecan-plus-bevacizumab-in-irinotecan-refractory-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05759728/un-estudio-de-cna3103-celulas-car-t-autologas-dirigidas-a-lgr5-administrado-a-sujetos-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05759728/a-study-of-cna3103-lgr5-targeted-autologous-car-t-cells-administered-to-subjects-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-tercera-linea-o-posterior-en-pacientes-con-mcrc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-plus-bevacizumab-as-a-third-line-or-beyond-therapy-in-mcrc-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04510129/un-estudio-multicentrico-de-recoleccion-de-bioespecimenes-de-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04510129/a-multicenter-cancer-biospecimen-collection-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06496919/investigacion-en-el-mundo-real-sobre-la-prevencion-y-el-tratamiento-de-la-metastasis-peritoneal-y-la-ascitis-maligna-mediante-la-infusion-intraperitoneal-de-rmhtnf-en-tumores-malignos-gastricos-y 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06496919/a-real-world-research-on-the-prevention-and-treatment-of-peritoneal-metastasis-and-malignant-ascites-by-intraperitoneal-infusion-of-rmhtnf-in-gastric-and-colorectal-malignant-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167409/un-estudio-de-evorpacept-alx148-en-combinacion-con-cetuximab-y-pembrolizumab-para-el-cancer-colorrectal-metastasico-refractario-con-estabilidad-de-microsatelites 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167409/a-study-of-evorpacept-alx148-with-cetuximab-and-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT01763125/creacion-de-un-biobanco-de-tumores-a-partir-de-muestras-de-sangre 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/establishment-of-a-tumor-bank-for-blood-samples 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/viabilidad-tecnica-de-la-quimioterapia-intraperitoneal-modificada-en-las-primeras-etapas-del-periodo-postoperatorio-mepic 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05913674/technical-feasibility-of-modified-early-post-operative-intraperitoneal-chemotherapy-mepic 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-en-pacientes-con-sarcoma-o-cancer-del-tracto-gastrointestinal 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-in-patients-with-sarcoma-or-gastrointestinal-tract-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409805/vacuna-ymn-136-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-que-presentan-progresion-tras-el-tratamiento-en-tercera-linea 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409805/ymn-136-vaccine-for-patients-with-liver-metastasis-of-colorectal-cancer-progressing-after-third-line-treatment 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06978400/un-estudio-de-dabrafenib-mas-cetuximab-panitumumab-con-folfox-en-la-primera-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/a-study-of-dabrafenib-plus-cetuximab-panitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-en-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-cancer-colorrectal-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06634875/isunakinra-alone-and-in-combination-with-pembrolizumab-in-patients-with-colorectal-cancer-mss 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/el-papel-del-perfil-molecular-tumoral-cms-el-genotipo-ugt1a1-y-la-actividad-de-la-beta-glucuronidasa-de-la-microbiota-intestinal-en-la-eficacia-del-tratamiento-la-toxicidad-la-supervivencia-y-la 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/the-role-of-the-tumor-molecular-profile-cms-ugt1a1-genotype-and-beta-glucuronidase-activity-of-the-intestinal-microbiota-for-treatment-efficiency-toxicity-survival-and-quality-of-life-in-patients 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06967155/un-estudio-de-irinotecan-con-dabrafenib-mas-trametinib-y-anti-egfr-en-la-segunda-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06967155/a-study-of-irinotecan-with-dabrafenib-plus-trametinib-and-anti-egfr-in-the-second-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06619886/terapia-con-celulas-t-modificadas-con-tcr-dirigido-a-tp53-r248-para-tumores-solidos-avanzados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06619886/tp53-r248q-tcr-t-cell-therapy-for-advanced-solid-tumor 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/estudio-de-fase-ii-de-liposomas-de-irinotecan-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/phase-ii-study-of-irinotecan-liposomes-in-first-line-treatment-of-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07009145/ql1706-mas-bevacizumab-para-el-cancer-colorrectal-irresecable-o-metastasico-msi-h-dmmr 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-h-dmmr-crc 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589830/tl938-y-trastuzumab-para-pacientes-con-cancer-colorrectal-metastasico-her2-positivo 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589830/tl938-and-trastuzumab-for-patients-with-her2-positive-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07591597/un-ensayo-clinico-multicentrico-de-fase-ib-ii-para-evaluar-la-eficacia-y-la-seguridad-de-la-terapia-combinada-concurrente-de-s-531011-mas-fruquintinib-o-s-531011-mas-fruquintinib-mas-pembrolizumab-en 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/a-multicenter-phase-ib-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-concurrent-combination-therapy-of-s-531011-plus-fruquintinib-or-s-531011-plus-fruquintinib-plus-pembrolizumab-in 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05022030/mcapox-cetuximab-frente-a-mfolfox6-cetuximab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-del-lado-izquierdo-con-genes-ras-braf-de-tipo-salvaje 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05022030/first-line-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-metastatic-left-sided-crc-with-wild-type-ras-braf-genes 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/un-estudio-de-seguridad-tolerabilidad-y-eficacia-de-nc410-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-irresecables-o-metastasicos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/a-safety-tolerability-and-efficacy-study-of-nc410-plus-pembrolizumab-in-participants-with-advanced-unresectable-or-metastatic-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/deteccion-de-metastasis-cerebrales-mediante-resonancia-magnetica-en-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/detection-of-brain-metastasis-by-mri-in-metastatic-colorectal-cancer-patients 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/un-estudio-de-la-combinacion-de-anlotinib-clorhidrato-en-capsulas-con-quimioterapia-como-tratamiento-de-primera-linea-en-sujetos-con-cancer-colorrectal-metastasico-ras-braf-tipo-salvaje 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/a-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-as-first-line-treatment-in-subjects-with-ras-braf-wild-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/ensayo-clinico-sobre-la-administracion-de-hipec-con-mitomicina-c-en-metastasis-peritoneales-del-cancer-de-colon-gecop-mmc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05250648/clinical-trial-on-hipec-with-mitomycin-c-in-colon-cancer-peritoneal-metastases-gecop-mmc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/un-estudio-para-obtener-mas-informacion-sobre-la-eficacia-y-la-seguridad-del-tratamiento-con-tabletas-de-sevabertinib-bay-2927088-en-participantes-que-tienen-un-tumor-solido-con-mutaciones-del 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-bay-2927088-tablets-works-and-how-safe-it-is-in-participants-who-have-a-solid-tumor-with-mutations-of-the-human-epidermal-growth 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223424/preferencias-del-paciente-con-respecto-a-la-administracion-subcutanea-frente-a-la-intravenosa-de-inmunoterapia 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223424/patient-preference-for-subcutaneous-vs-intravenous-immune-therapy 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/intervencion-basada-en-la-atencion-plena-para-parejas-en-el-contexto-del-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05840263/couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06640166/encorafenib-cetuximab-administracion-continuada-tras-la-progresion-en-combinacion-con-folfiri-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-que-progresa-tras-el-tratamiento 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06640166/encorafenib-cetuximab-beyond-progression-in-combination-with-folfiri-in-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-progressing-on-encorafenib-cetuximab 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/investigacion-genomica-de-pacientes-con-respuestas-inusuales 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/genomic-investigation-of-unusual-responders 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07463599/seguridad-y-eficacia-de-tegavivint-en-pacientes-con-carcinoma-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07463599/safety-and-efficacy-of-tegavivint-in-patients-with-metastatic-colorectal-carcinoma 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/ensayo-clinico-de-fase-ii-de-cadonilimab-en-combinacion-con-agentes-antiangiogenicos-en-el-cancer-colorrectal-metastasico-dmmr-msi-h 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/phase-ii-clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmr-msi-h-crc 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/seguridad-y-tolerabilidad-de-212pb-dotam-grpr1-en-sujetos-adultos-con-tumores-recurrentes-o-metastasicos-que-expresan-grpr 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/safety-and-tolerability-of-212pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-en-combinacion-con-trifluridina-tipiracil-y-bevacizumab-en-el-cancer-colorrectal-metastasico-recurrente 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-in-combination-with-trifluridine-tipiracil-and-bevacizumab-in-metastatic-recurrent-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06663839/un-estudio-de-nilk-2301-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-con-bajo-volumen-tumoral-ltv 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663839/a-study-of-nilk-2301-in-patients-with-locally-advanced-or-metastatic-low-tumor-volume-ltv-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05867303/estudio-rc198-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05867303/a-rc198-study-in-subjects-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07602504/base-de-datos-del-registro-clinico-chino-de-pacientes-con-cancer-de-higado-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/china-metastatic-liver-cancer-clinical-registry-cohort-database 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/terapia-sistemica-estandar-combinada-con-radioterapia-en-dosis-altas-bajas-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/standard-systemic-therapy-combined-with-high-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682247/un-estudio-en-el-mundo-real-de-chidamide-en-combinacion-con-anticuerpos-anti-pd-1-pd-l1-y-agentes-antiangiogenicos-en-el-cancer-colorrectal-avanzado-mss 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/a-real-world-study-of-chidamide-in-combination-with-pd-1-pd-l1-antibodies-and-anti-angiogenic-agents-in-advanced-mss-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integracion-de-los-patrones-de-crecimiento-histologico-peritoneal-en-la-toma-de-decisiones-preoperatorias-para-las-metastasis-peritoneales-del-cancer-colorrectal 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068103/pruebas-de-adn-tumoral-circulante-para-predecir-el-tratamiento-en-pacientes-con-cancer-de-colon-en-estadio-iia-despues-de-la-cirugia 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068103/circulating-tumor-dna-testing-in-predicting-treatment-for-patients-with-stage-iia-colon-cancer-after-surgery 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06447727/eficacia-y-seguridad-de-las-microesferas-de-90y-en-combinacion-con-folfiri-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-ccrm 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06447727/efficacy-and-safety-of-90y-microsphere-combined-with-folfiri-and-bevacizumab-in-second-line-treatment-of-crlm 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704010/endoscopia-con-capsula-en-el-sindrome-de-lynch 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704010/videocapsule-endoscopy-in-lynch-syndrome 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/estudio-de-inhibidores-de-ras-on-en-pacientes-con-tumores-solidos-gastrointestinales 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06445062/study-of-ras-on-inhibitors-in-patients-with-gastrointestinal-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06638931/terapia-agnostica-en-tumores-solidos-poco-frecuentes 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06638931/agnostic-therapy-in-rare-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-mas-durvalumab-con-o-sin-tremelimumab-en-pacientes-con-cancer-gastroesofagico-y-otras-neoplasias-gastrointestinales 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT03539822/cabozantinib-plus-durvalumab-with-or-without-tremelimumab-in-patients-with-gastroesophageal-cancer-and-other-gastrointestinal-malignancies 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118658/quimioterapia-secuencial-seguida-de-tislelizumab-tras-reseccion-radical-en-pacientes-con-dmmr-msi-h-o-mutaciones-en-los-genes-pole-pold1 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06118658/chemotherapy-sequential-tislelizumab-after-radical-resection-in-patients-with-dmmr-msi-h-or-pole-pold1-mutations 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04314401/banco-de-muestras-biologicas-del-programa-cancer-moonshot-del-instituto-nacional-del-cancer 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04314401/national-cancer-institute-cancer-moonshot-biobank 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT05669430/un-estudio-de-la-monoterapia-con-gv20-0251-y-la-combinacion-de-gv20-0251-con-pembrolizumab-en-participantes-con-tumores-solidos-malignos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05669430/a-study-of-gv20-0251-monotherapy-and-gv20-0251-in-combination-with-pembrolizumab-in-participants-with-solid-tumor-malignancies 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008797/un-estudio-de-e7386-en-combinacion-con-otros-farmacos-antineoplasicos-en-participantes-con-tumores-solidos 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008797/a-study-of-e7386-in-combination-with-other-anticancer-drug-s-in-participants-with-solid-tumor 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-en-combinacion-con-ataluren-en-pacientes-con-carcinoma-colorrectal-metastasico-pmmr-y-dmmr-o-carcinoma-endometrial-metastasico-dmmr-el-estudio-atapembro 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04014530/pembrolizumab-with-ataluren-in-patients-with-metastatic-pmmr-and-dmmr-colorectal-carcinoma-or-metastatic-dmmr-endometrial-carcinoma-the-atapembro-study 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/estudio-de-jyp0015-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-especificas-en-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07341737/sl-28-para-tumores-solidos-avanzados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07341737/sl-28-for-advanced-solid-tumours 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT07348211/primer-estudio-en-humanos-de-sim0610-en-tumores-solidos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT07348211/first-in-human-study-of-sim0610-in-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218914/estudio-de-fase-i-para-investigar-las-terapias-con-celulas-t-receptoras-quimericas-tcrt-dirigidas-a-la-mutacion-kras-en-tumores-solidos-avanzados-irresecables-y-o-metastasicos 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218914/phase-1-study-to-investigate-tcrts-kras-mutation-in-unresectable-advanced-and-or-metastatic-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05733000/cpi-613-devimistat-en-combinacion-con-hidroxicloroquina-y-5-fluorouracilo-o-gemcitabina-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-refractarios-a-la-quimioterapia 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT05733000/cpi-613-devimistat-in-combination-with-hydroxychloroquine-and-5-fluorouracil-or-gemcitabine-in-treating-patients-with-advanced-chemorefractory-solid-tumors 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04704661/evaluacion-de-la-combinacion-de-dos-farmacos-antineoplasicos-ds-8201a-y-azd6738-para-el-tratamiento-de-tumores-solidos-avanzados-que-expresan-la-proteina-o-el-gen-her2-ensayo-dash 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04704661/testing-the-combination-of-two-anti-cancer-drugs-ds-8201a-and-azd6738-for-the-treatment-of-advanced-solid-tumors-expressing-the-her2-protein-or-gene-the-dash-trial 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06466187/un-estudio-de-sgn-mesoc2-en-tumores-solidos-avanzados 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT06466187/a-study-of-sgn-mesoc2-in-advanced-solid-tumors 2026-05-27 weekly 0.6 https://crcwarriors.org/ensayo/NCT04485013/ttx-080-antagonista-de-hla-g-en-sujetos-con-canceres-avanzados 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT04485013/ttx-080-hla-g-antagonist-in-subjects-with-advanced-cancers 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06652672/cirugia-conservadora-del-ganglio-centinela-y-de-los-organos-en-el-carcinoma-de-colon-en-estadio-i 2026-05-27 weekly 0.7 https://crcwarriors.org/ensayo/NCT06652672/sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-04-14 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-04-14 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-04-15 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-04-15 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isunakinra 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isunakinra/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tu2218 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tu2218/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trisulfate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trisulfate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/liverpearls-irinotecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/liverpearls-irinotecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dkn-01 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dkn-01/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/icrucumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/icrucumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/treatme 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/treatme/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cnto-328 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cnto-328/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/es104 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/es104/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tc-510 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tc-510/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cu-tz-sara 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cu-tz-sara/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-awwb 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-awwb/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xl888 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl888/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pep503 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pep503/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-102 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ga-102/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/kzr-261 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kzr-261/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986490 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bms-986490/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/metarresti 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/metarresti/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eo2040 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/eo2040/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tak-186 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tak-186/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mgd009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mgd009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/qs21 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/qs21/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-706 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amg-706/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gen1042 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gen1042/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bempegaldesleukin 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bempegaldesleukin/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-05212384 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-05212384/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/catumaxomab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/catumaxomab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mva-209 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/mva-209/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/bnt314 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt314/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pb101 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pb101/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/cp-751 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cp-751/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nktr-262 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/nktr-262/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/nktr-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nktr-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golimumab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/golimumab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/prasterone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prasterone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt327 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt327/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gi-102 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gi-102/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/tinodasertib 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tinodasertib/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/danvatirsen 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/danvatirsen/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gen-011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gen-011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/menthol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/menthol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eco-4601 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/eco-4601/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/jmt108 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/jmt108/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/esg401 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/esg401/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/glucagon 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/glucagon/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/tas102 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/tas102/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/devimistat 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/devimistat/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/ak117 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/ak117/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/wnt974 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/wnt974/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-06946860 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-06946860/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/kqb368 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/kqb368/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/lt-002 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/lt-002/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/gdc-0994 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gdc-0994/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/disp-10 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/disp-10/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/clsp-1025 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/clsp-1025/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/paricalcitol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/paricalcitol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt803 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/alt803/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/dexpantenol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexpantenol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midostauri 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/midostauri/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ramosetron 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramosetron/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rph-030 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/rph-030/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/prednisolone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prednisolone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2236/presentamos-la-base-de-datos-j-connect-un-recurso-de-oncologia-del-mundo-real-para-japon 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2236/introducing-the-j-connect-database-a-real-world-oncology-resource-for-japan 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2217/la-inhibicion-de-la-autofagia-mejora-la-eficacia-del-bloqueo-de-pd-1-en-el-cancer-colorrectal-con-reparacion-del-desajuste-funcional-conservada 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2217/autophagy-inhibition-enhances-pd-1-blockade-efficacy-in-mismatch-repair-proficient-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2213/desarrollo-y-validacion-de-un-modelo-de-aprendizaje-automatico-de-conjunto-para-predecir-la-supervivencia-en-el-cancer-colorrectal-localmente-avanzado-un-estudio-retrospectivo-multicentrico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2213/development-and-validation-of-an-ensemble-machine-learning-model-to-predict-survival-in-locally-advanced-rectal-cancer-a-multicenter-retrospective-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2208/el-indice-pronostico-basado-en-biomarcadores-inflamatorios-ibpi-obtenido-a-partir-de-los-analisis-de-sangre-preoperatorios-estandar-predice-las-complicaciones-postoperatorias-en-pacientes-sometidos-a 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2208/the-inflammatory-biomarkers-prognostic-index-ibpi-obtained-from-standard-preoperative-blood-tests-predicts-postoperative-complications-in-patients-undergoing-pelvic-exenteration-for-locally-recurrent 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2199/sistema-de-administracion-oral-nano-vacunal-mucoadhesivo-con-capacidad-inmunomoduladora-para-una-terapia-sinergica-contra-el-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2199/mucoadhesive-oral-nanovaccine-delivery-system-with-immunomodulatory-capacity-for-synergistic-colorectal-cancer-therapy 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2187/significado-clinico-del-indice-pronostico-de-napoles-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2187/clinical-significance-of-the-naples-prognostic-score-in-patients-with-colorectal-liver-metastases 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2174/estudio-sobre-el-efecto-de-los-antibioticos-en-la-eficacia-de-los-inhibidores-de-pd-1-y-su-mecanismo-regulador-a-traves-de-la-comunidad-bacteriana-intestinal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2174/study-on-the-effect-of-antibiotics-on-the-efficacy-of-pd-1-inhibitors-and-its-regulatory-mechanism-via-the-intestinal-bacterial-community 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2163/el-regorafenib-potencia-la-eficacia-terapeutica-anti-pdcd1-pd-1-en-el-cancer-colorrectal-al-promover-la-degradacion-de-cd274-pd-l1-mediada-por-sqstm1-p62 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2163/regorafenib-enhances-anti-pdcd1-pd-1-therapeutic-efficacy-in-colorectal-cancer-by-promoting-sqstm1-p62-mediated-cd274-pd-l1-degradation 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2150/el-papel-del-adn-tumoral-circulante-en-la-terapia-adyuvante-de-precision-para-el-cancer-colorrectal-una-revision-exploratoria 2026-05-23 monthly 0.5 https://crcwarriors.org/articulo/2150/the-role-of-circulating-tumor-dna-in-precision-adjuvant-therapy-for-colorectal-cancer-a-scoping-review 2026-05-23 monthly 0.5 https://crcwarriors.org/articulo/2143/la-privacion-del-sueno-inhibe-la-funcion-de-los-linfocitos-t-cd8-al-aumentar-la-expresion-de-galectina-9-en-las-celulas-de-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2143/sleep-deprivation-inhibits-cd8-t-cell-function-by-elevating-galectin-9-expression-in-colorectal-cancer-cells 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2118/ensayo-fruquitas-diseno-del-estudio-de-un-ensayo-aleatorizado-de-fase-iii-del-grupo-de-colaboracion-engic-que-evalua-la-combinacion-de-trifluridina-tipiracil-con-o-sin-fruquintinib-en-pacientes-con 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2118/fruquitas-trial-study-design-of-an-engic-intergroup-randomized-phase-iii-of-trifluridine-tipiracil-fruquintinib-in-pre-treated-metastatic-gastro-oesophageal-adenocarcinoma 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2103/creacion-de-una-plataforma-solida-para-estudios-iniciados-por-investigadores-la-experiencia-de-i-care 2026-05-21 monthly 0.5 https://crcwarriors.org/articulo/2103/building-a-robust-investigator-initiated-platform-the-i-care-experience 2026-05-21 monthly 0.5 https://crcwarriors.org/articulo/2074/ingenieria-de-nanocapsulas-para-la-silenciamiento-eficiente-de-nsun2-y-una-terapia-inmunomoduladora-en-el-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2074/nanocarriers-engineering-for-efficient-nsun2-silencing-and-immune-responsive-therapy-in-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2069/oncogenicidad-e-implicaciones-terapeuticas-de-los-biomarcadores-moleculares-en-el-carcinoma-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2069/oncogenicity-and-therapeutic-implications-of-molecular-biomarkers-in-colorectal-carcinoma 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2027/inmunoterapia-en-el-cancer-colorrectal-localizado-practica-actual-y-perspectivas-futuras 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2027/immunotherapy-in-localized-colorectal-cancer-current-practice-and-future-directions 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2020/nivolumab-mas-ipilimumab-y-cobimetinib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-del-emparejamiento-del-adn-previamente-tratados-el-ensayo-de 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2020/nivolumab-plus-ipilimumab-and-cobimetinib-in-previously-treated-microsatellite-stable-dna-mismatch-repair-proficient-metastatic-colorectal-cancer-the-phase-ii-checkmate-142-trial 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1999/el-inhibidor-selectivo-de-kras-g12d-mrtx1133-suprime-la-proliferacion-y-modula-diferencialmente-la-quimiosensibilidad-en-el-carcinoma-mucinoso-de-ovario 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1999/kras-g12d-selective-inhibitor-mrtx1133-suppresses-proliferation-and-differentially-modulates-chemosensitivity-in-ovarian-mucinous-carcinoma 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1980/datos-sobre-las-firmas-transcriptomicas-de-microarn-los-genes-diana-predichos-y-el-analisis-de-vias-de-senalizacion-en-respuesta-a-cetuximab-o-panitumumab-en-celulas-de-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1980/data-on-microrna-transcriptomic-signatures-predicted-gene-targets-and-pathway-analysis-in-response-to-cetuximab-or-panitumumab-in-colorectal-cancer-cells 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1978/nuevos-y-consolidados-objetivos-terapeuticos-en-el-cancer-colorrectal-traslacion-de-la-biologia-a-la-terapia 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1978/emerging-and-established-targets-in-colorectal-cancer-translating-biology-into-therapeutics 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1977/la-validacion-integrada-a-traves-de-la-transcriptomica-y-la-proteomica-identifica-a-slc35d3-como-un-antigeno-de-superficie-selectivo-para-tumores-en-los-carcinomas-colorrectales-y-neuroendocrinos 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1977/integrated-transcriptomic-and-proteomic-validation-identifies-slc35d3-as-a-tumor-selective-surface-antigen-for-colorectal-and-neuroendocrine-carcinomas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1976/identificacion-preclinica-y-validacion-clinica-de-biomarcadores-dinamicos-para-trifluridina-tipiracil-con-o-sin-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1976/preclinical-identification-and-clinical-validation-of-dynamic-biomarkers-for-trifluridine-tipiracil-with-or-without-bevacizumab-in-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1974/eficacia-y-seguridad-del-tratamiento-de-segunda-linea-con-fluorouracilo-leucovorina-e-irinotecan-mas-ramucirumab-segun-los-regimenes-previos-de-primera-linea-en-el-cancer-colorrectal-metastasico-un 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1974/efficacy-and-safety-of-second-line-fluorouracil-leucovorin-and-irinotecan-plus-ramucirumab-according-to-prior-first-line-regimens-in-metastatic-colorectal-cancer-a-multicenter-retrospective-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1955/relevancia-pronostica-y-para-el-seguimiento-del-oxido-nitrico-sistemico-en-pacientes-con-cancer-de-colon 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1955/prognostic-and-monitoring-relevance-of-systemic-nitric-oxide-in-patients-with-colon-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1950/una-nanoparticula-hibrida-con-membrana-que-mimetiza-y-modula-la-respuesta-inmune-mediante-fototermia-inhibe-el-crecimiento-y-la-metastasis-del-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1950/hybrid-membrane-camouflaged-photothermal-immunomodulatory-nanoparticle-inhibits-colorectal-cancer-growth-and-metastasis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1888/camino-a-seguir-crioablacion-para-metastasis-hepaticas-de-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1888/path-forward-cryoablation-for-colorectal-liver-metastases 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1876/prediccion-de-dmmr-a-partir-de-histopatologia-de-cancer-colorrectal-aprovechamiento-de-regiones-no-tumorales-y-de-bajo-aumento 2026-05-23 monthly 0.5 https://crcwarriors.org/articulo/1876/dmmr-prediction-from-colorectal-cancer-histopathology-leveraging-non-tumor-and-low-magnification-regions 2026-05-23 monthly 0.5 https://crcwarriors.org/articulo/1856/los-estudios-sobre-los-caf-hipoxicos-revelan-que-el-eje-pthrp-vitamina-d-ras-es-fundamental-en-los-caf 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1856/hypoxic-caf-studies-unveil-pthrp-vitamin-d-ras-axis-as-pivotal-in-the-caf 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1814/el-analisis-integrado-de-la-transcriptomica-unicelular-y-espacial-revela-el-microambiente-del-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1814/integrated-single-cell-and-spatial-transcriptomics-reveal-the-colorectal-cancer-microenvironment 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1738/tnmplot-una-plataforma-mejorada-para-la-identificacion-de-dianas-farmacologicas-mediante-el-analisis-de-la-expresion-genica-en-diferentes-estadios-y-en-diversos-tipos-de-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1738/tnmplot-an-enhanced-platform-for-pharmacological-target-identification-through-cross-stage-and-pan-cancer-gene-expression-analysis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1644/el-doble-papel-del-receptor-de-peptidos-formilados-1-fpr1-en-la-inflamacion-y-la-carcinogenesis-gastrointestinal-mecanismos-e-implicaciones-terapeuticas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1644/the-dual-role-of-formyl-peptide-receptor-1-fpr1-in-gastrointestinal-inflammation-and-carcinogenesis-mechanisms-and-therapeutic-implications 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1511/cambios-en-la-6a-edicion-de-la-clasificacion-de-la-organizacion-mundial-de-la-salud-de-los-tumores-del-sistema-digestivo 2026-05-22 monthly 0.5 https://crcwarriors.org/articulo/1511/changes-in-the-6th-edition-of-the-world-health-organization-classification-of-tumours-of-the-digestive-system 2026-05-22 monthly 0.5 https://crcwarriors.org/articulo/1030/utilidad-clinica-del-analisis-longitudinal-de-adn-tumoral-circulante-en-pacientes-con-cancer-colorrectal-metastasico-que-reciben-quimioterapia-paliativa 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1030/clinical-utility-of-longitudinal-circulating-tumor-dna-analysis-in-metastatic-colorectal-cancer-patients-receiving-palliative-chemotherapy 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1003/evaluacion-inmunohistoquimica-de-la-expresion-de-proteina-egfr-y-densidad-microvascular-revela-una-firma-angiogenica-en-pacientes-tunecinos-con-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/1003/immunohistochemical-evaluation-of-egfr-protein-expression-and-microvascular-density-reveals-an-angiogenic-signature-in-tunisian-patients-with-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/838/implicaciones-clinicas-y-pronosticas-de-las-mutaciones-de-ras-en-el-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/838/clinical-and-prognostic-implications-of-ras-mutations-in-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2235/respuesta-duradera-a-selpercatinib-en-un-cancer-colorrectal-metastasico-que-presenta-una-nueva-fusion-timm23b-ret-informe-de-un-caso 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2235/durable-response-to-selpercatinib-in-metastatic-colorectal-cancer-harboring-a-novel-timm23b-ret-fusion-a-case-report 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2234/respuesta-patologica-completa-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-con-deficiencia-en-el-sistema-de-reparacion-de-errores-mismatch-repair-e-invasion-de-organos-adyacentes 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2234/complete-pathologic-response-after-neoadjuvant-immunotherapy-for-mismatch-repair-deficient-colon-cancer-with-invading-adjacent-organs 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2232/la-plataforma-de-oncologia-de-precision-funcional-de-organoides-de-cancer-colorrectal-con-mutacion-braf-v600e-predice-la-respuesta-al-tratamiento-y-revela-la-inmunogenicidad-mediada-por-rnf43 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2232/functional-precision-oncology-platform-of-braf-v600e-mutated-colorectal-cancer-organoids-predicts-therapy-response-and-reveals-rnf43-mediated-immunogenicity 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2231/analisis-de-costo-efectividad-del-encorafenib-en-cancer-colorrectal-metastasico-braf-v600e-no-tratado-en-china 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2231/cost-effectiveness-analysis-of-encorafenib-in-untreated-braf-v600e-mutant-metastatic-colorectal-cancer-in-china 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2226/preactivacion-con-citocinas-y-citotoxicidad-celular-dependiente-de-anticuerpos-adcc-una-estrategia-eficaz-para-potenciar-las-funciones-efectoras-de-las-celulas-nk-humanas-frente-a-modelos-tumorales 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2226/cytokine-preactivation-and-adcc-a-potent-strategy-for-enhancing-human-nk-cell-effector-functions-against-3d-tumor-models 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2225/estudio-multicentrico-de-fase-ii-que-evalua-el-regimen-folfoxiri-neoadyuvante-seguido-de-quimiorradioterapia-concurrente-en-pacientes-chinos-con-cancer-de-recto-de-alto-riesgo 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2225/multicenter-phase-ii-study-of-neoadjuvant-folfoxiri-followed-by-concurrent-chemoradiotherapy-in-chinese-patients-with-high-risk-rectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2224/alteracion-del-ritmo-circadiano-en-el-cancer-colorrectal-la-cronoterapia-como-una-prometedora-estrategia-de-medicina-de-precision 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2224/circadian-disruption-in-colorectal-cancer-promise-of-chronotherapy-as-precision-medicine 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2221/analisis-de-la-toxicidad-a-lo-largo-del-tiempo-de-la-terapia-de-mantenimiento-basada-en-anti-egfr-frente-a-la-estrategia-de-tratamiento-intermitente-en-el-cancer-colorrectal-metastasico-del-lado 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2221/toxicity-over-time-analysis-of-anti-egfr-based-maintenance-versus-stop-go-in-left-sided-ras-braf-wild-type-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2220/la-nanomedicina-que-se-adhiere-a-los-macrofagos-y-coadministra-gemcitabina-e-inhibidor-de-kras-g12d-orquesta-una-quimioinmunoterapia-para-el-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2220/macrophage-hitchhiking-nanomedicine-codelivering-gemcitabine-and-kras-g12d-inhibitor-orchestrates-chemo-immunotherapy-for-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2219/biosintesis-de-nanoparticulas-de-metales-preciosos-utilizando-extractos-de-algas-verdes-para-la-terapia-del-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2219/biosynthesis-of-precious-metal-nanoparticles-using-green-algae-extracts-for-cancer-therapy 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2218/nanoparticulas-para-la-terapia-del-cancer-colorrectal-una-revision 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2218/nanoparticles-for-colorectal-cancer-therapy-a-review 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2212/metastasis-hepaticas-de-cancer-colorrectal-estrategias-de-imagen-para-el-diagnostico-la-planificacion-del-tratamiento-local-y-la-evaluacion-de-la-respuesta-al-tratamiento-sistemico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2212/colorectal-liver-metastases-imaging-strategies-for-diagnosis-local-treatment-planning-and-systemic-treatment-response 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2209/camk1-suprime-la-resistencia-a-la-anoikis-y-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2209/camk1-suppresses-anoikis-resistance-and-liver-metastasis-in-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2207/estudio-mecanicista-de-la-regulacion-farmacodinamica-en-la-tumorigenesis-modificacion-epigenetica-de-enzimas-clave-mediante-componentes-activos-de-ginsenosidos 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2207/mechanistic-study-of-pharmacodynamic-regulation-in-tumorigenesis-epigenetic-targeting-of-key-enzymes-by-active-ginsenoside-components 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2206/el-papel-de-la-proteina-quinasa-ii-dependiente-de-ca-2-calmodulina-en-la-resistencia-al-oxaliplatino-del-cancer-colorrectal-estudios-in-vitro-e-in-vivo 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2206/the-role-of-ca-2-calmodulin-dependent-protein-kinase-ii-in-oxaliplatin-resistance-of-colorectal-cancer-in-vitro-and-in-vivo-studies 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2205/comparacion-indirecta-ajustada-por-emparejamiento-de-sotorasib-mas-panitumumab-frente-a-trifluridina-tipiracilo-mas-bevacizumab-en-cancer-colorrectal-metastasico-quimiorrefractario 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2205/matching-adjusted-indirect-comparison-of-sotorasib-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-in-chemorefractory-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2200/los-anticuerpos-bispecificos-dirigidos-al-tumor-inhiben-eficazmente-las-vias-oncogenicas-al-tiempo-que-minimizan-la-toxicidad 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2200/tumor-targeted-bispecific-antibodies-effectively-inhibit-oncogenic-pathways-while-minimizing-toxicity 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2198/un-modelo-de-deteccion-automatica-de-la-diseminacion-a-traves-de-los-espacios-aereos-en-secciones-patologicas-postoperatorias-basado-en-el-aprendizaje-profundo-en-el-cancer-de-pulmon-no-microcitico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2198/an-automatic-detection-model-for-spread-through-air-spaces-in-postoperative-pathological-sections-based-on-deep-learning-in-nsclc 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2197/deteccion-del-cancer-estratificada-segun-el-riesgo-un-modelo-conceptual-basado-en-el-consenso-de-eucanscreen 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2197/risk-stratified-cancer-screening-a-consensus-based-conceptual-framework-from-eucanscreen 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2194/analisis-de-la-eficacia-y-los-riesgos-de-la-monoterapia-y-la-inmunoterapia-combinada-en-el-cancer-colorrectal-metastasico-con-dmmr-msi-h-un-metaanalisis-basado-en-ensayos-clinicos-aleatorizados-y 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2194/efficacy-and-risk-analysis-of-monotherapy-and-dual-immunotherapy-in-dmmr-msi-h-metastatic-colorectal-cancer-a-meta-analysis-based-on-randomized-controlled-trials 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2193/complete-remission-following-targeted-therapy-in-braf-v600e-mutant-pulmonary-lymphangitic-carcinomatosis-secondary-to-rectal-cancer-a-case-report 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2192/los-subtipos-de-mutacion-de-kras-permiten-una-mejor-estratificacion-pronostica-en-el-cancer-colorrectal-un-estudio-retrospectivo-de-cohortes 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2192/kras-mutation-subtypes-refine-prognostic-stratification-in-colorectal-cancer-a-retrospective-cohort-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2189/comentarios-sobre-el-articulo-titulado-el-potencial-diagnostico-de-los-compuestos-organicos-volatiles-en-la-orina-para-la-deteccion-de-neoplasias-colorrectales-en-el-sindrome-de-lynch-un-estudio 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2189/comments-on-the-diagnostic-potential-of-urinary-volatile-organic-compounds-for-colorectal-neoplasia-in-lynch-syndrome-a-prospective-longitudinal-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2186/diseno-sintesis-y-estudio-de-la-relacion-estructura-actividad-de-nuevos-compuestos-con-un-andamiaje-de-indolo-pirrol-dirigidos-a-nur77-en-celulas-tumorales-de-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2186/design-synthesis-and-structure-activity-relationship-study-of-novel-indole-pyrrole-scaffold-compounds-targeting-nur77-in-colorectal-tumor-cells 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2185/la-deteccion-frecuente-de-mutaciones-en-kras-g12c-y-pik3ca-q546k-en-tumores-map-pone-de-relieve-su-papel-en-la-reclasificacion-de-variantes-mutyh-de-significado-incierto 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2185/frequent-detection-of-kras-g12c-and-pik3ca-q546k-mutations-in-map-tumors-highlights-their-role-in-mutyh-variants-of-uncertain-significance-reclassification 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2183/las-mutaciones-de-kras-y-braf-modifican-los-resultados-de-la-quimioterapia-adyuvante-en-el-cancer-colorrectal-en-estadio-temprano 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2183/kras-and-braf-mutations-modify-adjuvant-chemotherapy-outcomes-in-early-stage-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2179/biomarcadores-plasmaticos-asociados-con-los-resultados-clinicos-del-regimen-folfiri-mas-ramucirumab-en-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-el-ensayo-jaccro-cc-16ar 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2179/plasma-biomarkers-associated-with-clinical-outcomes-of-folfiri-plus-ramucirumab-in-ras-wild-type-metastatic-colorectal-cancer-the-jaccro-cc-16ar-trial 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2178/efectos-pronosticos-y-relacionados-con-el-tratamiento-sobre-la-supervivencia-de-la-inestabilidad-de-microsatelites-en-los-diferentes-estadios-de-la-enfermedad-en-el-cancer-de-colon-un-analisis-de-la 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2178/prognostic-and-treatment-associated-survival-effects-of-microsatellite-instability-across-disease-stages-in-colon-cancer-an-ncdb-analysis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2176/establecimiento-de-una-radioinmunodiagnosis-predirigida-basada-en-68-ga-dota 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2176/establishment-of-68-ga-dota-based-pretargeted-radioimmunodiagnosis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2173/un-ensayo-clinico-nacional-multicentrico-aleatorizado-controlado-de-grupos-paralelos-de-fase-iii-que-compara-el-tratamiento-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-al-tratamiento 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2173/a-national-multicentre-randomised-controlled-parallel-arms-phase-iii-clinical-trial-of-neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-in-patients 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2171/adn-tumoral-circulante-y-biomarcadores-de-precision-en-el-cancer-colorrectal-implicaciones-para-el-diagnostico-seguimiento-y-manejo-de-la-enfermedad-avanzada 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2171/circulating-tumor-dna-and-precision-biomarkers-in-colorectal-cancer-implications-for-diagnosis-monitoring-and-management-of-advanced-disease 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2170/la-via-de-senalizacion-mapk-erk-en-el-cancer-colorrectal-avances-recientes-y-nuevos-conocimientos 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2170/the-mapk-erk-signaling-pathway-in-colorectal-cancer-recent-advances-and-emerging-insights 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2162/mutaciones-oncogenicas-frecuentes-en-el-cancer-colorrectal-factores-clave-en-la-carcinogenesis-y-posibles-dianas-terapeuticas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2162/common-oncogenic-mutations-in-colorectal-cancer-drivers-of-carcinogenesis-and-potential-therapeutic-targets 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2160/oncologia-de-precision-facilitada-por-la-cirugia-en-un-sarcoma-de-la-arteria-pulmonar-msi-h-con-sindrome-de-lynch-un-caso-clinico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2160/surgery-enabled-precision-oncology-in-an-msi-high-pulmonary-artery-sarcoma-with-lynch-syndrome-a-case-report 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluacion-del-ct-adn-y-el-estado-mutacional-en-la-biopsia-liquida-de-pacientes-con-cancer-colorrectal-metastasico 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluation-of-ct-dna-and-mutational-status-in-liquid-biopsy-of-patients-with-metastatic-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2156/caracterizacion-preclinica-y-resultados-de-la-fase-1-de-tqb2102-un-conjugado-anticuerpo-farmaco-biparatopico-her2-de-primera-generacion-en-pacientes-con-tumores-solidos-avanzados 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2156/preclinical-characterization-and-phase-1-results-of-tqb2102-a-first-in-class-her2-biparatopic-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2153/caracteristicas-y-resultados-de-pacientes-con-neoplasias-previas-al-cancer-colorrectal-un-analisis-de-concordancia-por-puntuacion-de-propension 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2153/characteristics-and-outcomes-of-patients-with-malignancies-prior-to-colorectal-cancer-a-propensity-score-matched-analysis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-y-cancer-de-ovario-evidencia-epidemiologica-conocimientos-moleculares-y-toma-de-decisiones-clinicas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-and-ovarian-cancer-epidemiological-evidence-molecular-insights-and-clinical-decision-making 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2149/ensayo-de-adn-tumoral-circulante-libre-de-tejido-y-resultados-en-pacientes-en-un-ensayo-de-fase-iii-de-quimioterapia-adyuvante-basada-en-folfox-alliance-n0147 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2149/tissue-free-circulating-tumor-dna-assay-and-patient-outcome-in-a-phase-iii-trial-of-folfox-based-adjuvant-chemotherapy-alliance-n0147 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2148/un-modelo-basado-en-organoides-ortotopicos-para-estudiar-la-disfuncion-temprana-de-celulas-t-cd8-y-la-respuesta-a-la-inmunoterapia-en-el-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2148/an-orthotopic-organoid-based-model-to-study-early-cd8-t-cell-dysfunction-and-immunotherapy-response-in-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2144/terapia-con-celulas-v1t-car-alogenicas-dirigidas-contra-b7-h3-en-tumores-solidos-avanzados-un-estudio-de-fase-i 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2144/allogeneic-b7-h3-targeted-car-v1t-cell-therapy-in-advanced-solid-tumors-a-phase-i-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutina-como-flavonoide-bioactivo-perspectivas-sobre-sus-mecanismos-anticancerigenos-y-aplicaciones-terapeuticas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutin-as-a-bioactive-flavonoid-insights-into-its-anticancer-mechanisms-and-therapeutic-applications 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2132/optimizacion-estructural-de-los-inhibidores-de-la-tirosil-adn-fosfodiesterasa-1-basados-en-benzofenantridinona-y-benzofenantridina-y-su-actividad-de-potenciacion-de-la-radioterapia 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2132/structural-optimization-of-benzophenanthridinone-and-benzophenanthridine-tyrosyl-dna-phosphodiesterase-1-inhibitors-and-their-radiosensitizing-activity 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2127/seguridad-y-eficacia-de-folfiri-3-irinotecan-en-dosis-divididas-para-el-cancer-colorrectal-irresecable-un-analisis-estratificado-basado-en-los-polimorfismos-del-gen-ugt1a1 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2127/safety-and-efficacy-of-folfiri-3-split-dose-irinotecan-for-unresectable-colorectal-cancer-a-stratified-analysis-based-on-ugt1a1-gene-polymorphisms 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2126/evaluaciones-pragmaticas-de-tecnologias-sanitarias-de-biosimilares-un-estudio-piloto-sobre-el-uso-de-bevacizumab-en-el-cancer-colorrectal-para-nice 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2126/pragmatic-health-technology-appraisals-of-biosimilars-a-pilot-case-study-of-bevacizumab-in-colorectal-cancer-for-nice 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2125/quimioterapia-supramolecular-visualizada-basada-en-oxpt-ttvp-cb-8-activacion-del-dano-oxidativo-para-inducir-la-muerte-celular-programada-inmunogenica-y-potenciar-la-eliminacion-de-las-celulas 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2125/supramolecular-visualized-chemotherapy-based-on-oxpt-ttvp-cb-8-activating-oxidative-damage-to-induce-icd-for-enhancing-the-killing-of-tumor-cells 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2122/informe-de-caso-adenocarcinomas-colorrectales-sincronicos-con-estado-de-reparacion-del-desajuste-discordante-un-caso-de-sindrome-similar-a-lynch-y-asociacion-con-la-via-serrada 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2122/case-report-synchronous-colorectal-adenocarcinomas-with-discordant-mismatch-repair-status-a-case-of-lynch-like-syndrome-and-serrated-pathway-association 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2120/el-acido-urico-soluble-induce-el-agotamiento-de-los-linfocitos-t-cd8-al-provocar-una-hiperactivacion-mediada-por-ksr1-de-la-via-mapk 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2120/soluble-uric-acid-drives-cd8-t-cell-exhaustion-by-inducing-ksr1-mediated-mapk-hyperactivation 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2113/panorama-genomico-completo-de-erbb2-en-tumores-gastrointestinales-chinos-panoramas-centrados-en-mutaciones-y-oportunidades-de-tratamiento-de-precision 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2113/comprehensive-genomic-landscape-of-erbb2-in-chinese-gi-tumors-mutation-centered-landscapes-and-precision-treatment-opportunities 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2112/el-ensayo-sherpa-un-estudio-de-fase-i-que-combina-el-inhibidor-de-shp2-rmc-4630-y-el-inhibidor-de-erk-ly3214996-en-pacientes-con-cancer-de-pancreas-cancer-de-pulmon-no-microcitico-y-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2112/the-sherpa-trial-a-phase-i-study-combining-shp2-inhibitor-rmc-4630-and-erk-inhibitor-ly3214996-in-patients-with-kras-mutant-pancreatic-non-small-cell-lung-and-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2111/optimizacion-de-la-terapia-con-pembrolizumab-para-el-cancer-colorrectal-metastasico-de-novo-msi-h-dmmr-mediante-el-uso-de-ecuaciones-integro-diferenciales-basadas-en-datos 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2111/optimisation-of-pembrolizumab-therapy-for-de-novo-metastatic-msi-h-dmmr-colorectal-cancer-using-data-driven-delay-integro-differential-equations 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2110/las-mutaciones-que-son-el-objetivo-de-la-inmunoterapia-nous-209-aparecen-en-las-primeras-etapas-de-las-lesiones-precancerosas-de-los-portadores-del-sindrome-de-lynch-que-presentan-inestabilidad-de 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2110/mutations-targeted-by-nous-209-immunotherapy-occur-early-in-lynch-syndrome-carriers-precancer-lesions-with-microsatellite-instability 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2105/la-decoccion-de-dabupi-atenua-la-mucositis-intestinal-inducida-por-fluorouracilo-mediante-la-activacion-del-receptor-x-farnesoide-y-la-regulacion-al-alza-de-la-dihidropirimidina-deshidrogenasa 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2105/dabupi-decoction-mitigates-fluorouracil-induced-intestinal-mucositis-via-farnesoid-x-receptor-activation-and-dihydropyrimidine-dehydrogenase-upregulation 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2102/la-transcripcion-y-el-empalme-no-canonicos-modelan-el-inmunopeptidoma-del-cancer-colorrectal-en-tumores-msi-y-mss 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2102/non-canonical-transcription-and-splicing-shape-the-colorectal-cancer-immunopeptidome-in-msi-and-mss-tumors 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2099/alteracion-de-la-interaccion-entre-el-lipopolisacarido-bacteriano-y-las-celulas-inmunitarias-en-el-cancer-colorrectal-en-comparacion-con-el-tejido-intestinal-adyacente 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2099/altered-crosstalk-of-bacterial-lipopolysaccharide-with-immune-cells-in-colorectal-cancer-compared-to-paired-adjacent-intestinal-tissue 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2094/puntuacion-revisada-de-la-carga-tumoral-para-la-estratificacion-pronostica-en-pacientes-con-cancer-colorrectal-metastasico-que-reciben-inmunoterapia-un-estudio-retrospectivo 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2094/revised-tumor-burden-score-for-prognostic-stratification-in-metastatic-colorectal-cancer-patients-receiving-immunotherapy-a-retrospective-study 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2093/toward-targeting-the-untargetable-un-conjugado-egfr-peptido-farmaco-no-canonico-logra-una-potente-actividad-antitumoral-en-el-ccr-con-mutacion-de-kras 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2093/toward-targeting-the-untargetable-a-non-canonical-egfr-peptide-drug-conjugate-achieves-potent-antitumor-activity-in-kras-mutant-crc 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2087/resistencia-adquirida-a-los-inhibidores-de-los-puntos-de-control-inmunitario-en-diversos-tipos-de-tumores-un-analisis-reconstruido-de-datos-individuales-de-pacientes 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2087/acquired-resistance-to-immune-checkpoint-inhibitors-across-tumor-types-a-reconstructed-individual-patient-data-analysis 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2086/aprendizaje-profundo-basado-en-laminas-histologicas-de-cd3-para-la-prediccion-del-pronostico-del-cancer-de-colon-analisis-de-tres-cohortes-internacionales-de-cancer-de-colon-en-estadio-iii 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2086/deep-learning-based-on-cd3-histological-slides-for-prediction-of-colon-cancer-outcome-analysis-of-three-international-stage-iii-colon-cancer-cohorts 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2081/mutaciones-geneticas-que-rigen-la-sensibilidad-y-la-resistencia-a-la-ferroptosis-un-enfoque-de-precision-para-la-terapia-del-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2081/genetic-mutations-governing-ferroptosis-sensitivity-and-resistance-a-precision-approach-to-cancer-therapy 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2080/un-estado-celular-con-alta-activacion-de-la-via-mapk-y-baja-activacion-de-la-via-wnt-favorece-la-diseminacion-metastasica-en-el-cancer-colorrectal 2026-05-27 monthly 0.5 https://crcwarriors.org/articulo/2080/a-high-mapk-low-wnt-cell-state-drives-metastatic-dissemination-in-colorectal-cancer 2026-05-27 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-05-24 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-05-20 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-05-21 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-05-24 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-05-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-05-01 monthly 0.4